Thus, patients with the HR+ or HER2− phenotype in the high-risk group were more likely to be resistant to CDK4/6 inhibitors, and we inferred that our cuproptosis-related model facilitates the identification of patients with BC who are more susceptible to CKD4/6 inhibitor resistance. Here, ERBB2 is linked to breast cancer.